Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 13/20 | 0.66 |
| ▸ | THRA | P10827 | 11/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398358 | 0.87 | THRA (0.56) | THRBTHRAMEN1KMT2APOLB | |
| SCHEMBL5387103 | 0.83 | THRB (0.64) | THRBTHRAMEN1KMT2APOLB | |
| SCHEMBL5387389 | 0.83 | THRA (0.88) | THRBTHRA | |
| SCHEMBL5387098 | 0.81 | THRB (0.73) | THRBTHRAPOLBRORCMAPK1 | |
| SCHEMBL5385243 | 0.80 | THRA (0.60) | THRBTHRAMEN1KMT2APOLB | |
| SCHEMBL5382644 | 0.80 | THRB (0.60) | THRBTHRAMEN1KMT2APOLB | |
| SCHEMBL5392866 | 0.79 | THRA (1.00) | THRBTHRA | |
| SCHEMBL5382648 | 0.78 | THRB (0.60) | THRBTHRAMEN1KMT2APOLB | |
| SCHEMBL5388467 | 0.78 | THRB (0.72) | THRBTHRARORC | |
| SCHEMBL5381969 | 0.77 | THRB (0.59) | THRBTHRAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199265-B2 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2004-05-20 | — | — | US | disclosed |
| EP-1296936-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098256-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | TSHR, THRA, THRB | THRB 3/4885THRA 2/4885MEN1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.